DrugPatentWatch Database Preview
Litigation Details for Endo Pharmaceuticals Inc. v. Roxane Laboratories, Inc. (S.D.N.Y. 2013)
» See Plans and Pricing
Endo Pharmaceuticals Inc. v. Roxane Laboratories, Inc. (S.D.N.Y. 2013)
| Docket | Start Trial | Date Filed | 2013-05-15 |
| Court | District Court, S.D. New York | Date Terminated | |
| Cause | 35:145 Civil Action to Obtain Patent | Assigned To | Thomas Poole Griesa |
| Jury Demand | None | Referred To | |
| Patents | 7,276,250; 7,851,482; 8,114,383; 8,192,722; 8,309,122; 8,329,216; 8,808,737; 8,871,779 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Endo Pharmaceuticals Inc. v. Roxane Laboratories, Inc.
The small molecule drugs covered by the patents cited in this case are Start Trial , Start Trial , and Start Trial .
Details for Endo Pharmaceuticals Inc. v. Roxane Laboratories, Inc. (S.D.N.Y. 2013)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2014-11-21 | 101 | validity of U.S. Patent No. 7,851,482 (“’482 patent”), U.S. Patent No. 8,309,122 (“‘122 patent”) and U.S. …validly construed claim of U.S. Patent No. 7,851,482 (“the ‘482 patent”) either literally or under the…filed this lawsuit asserting U.S. Patent No. 7,851,482 (“the ‘482 patent”) against Roxane with knowledge… Declaring that the patent claims in United States Patent No. 7,851,482 are invalid for failure … (Noninfringement of U.S. Patent No. 7,851,482) 2. The manufacture, use, sale | External link to document | |
| 2015-03-05 | 112 | 7, and 9 of U.S. Patent No. 8,114,383 (“the ’383 patent”). Those same ‘383 patent claims have been the…to be tried with respect to Endo’s ‘482 patent and ‘383 patent. We write to provide Your Honor with the…instituted by the Patent & Trademark Office (“PTO”) in connection with that patent. Those proceedings… claims of the ‘482 Patent. See Exs. 1 and 2 hereto. Cancelled patent claims cannot be asserted…claims 1, 2, 5, and 7 of the ’383 patent, and the only ‘383 patent claim that Plaintiffs will assert | External link to document | |
| 2015-03-09 | 126 | application which later issued as U.S. Patent No. 8,309,122 (“the ‘122 patent”) at issue in this litigation. …that apply to the ‘122 patent and to U.S. Patent No. 8,329,216 (“the ‘216 patent”) in suit here. Those…and the same or related Endo patent applications that led to the patents-in-suit. In In re Kao… of a decision of the U.S. Patent and Trademark Office’s Board of Patent Appeals and Interferences (“…upheld the patent office’s determination that the pending claims of certain of Endo’s patent applications | External link to document | |
| 2015-03-12 | 134 | . Patent No. 7,276,250 (“‘250 patent”) . 3 ….................................3 U.S. Patent No. 7,276,250.........................................… † U,S. Patent No. 5,958,456 (“‘456 patent”), U.S. Patent No. 5,662,933 (“‘933 patent”), and U.S. …Roxane on three additional patents: the ‘482 patent, ‘122 patent, and ‘216 patent, claiming that Roxane’s…formulation of Opana® ER: the ‘933 patent, ’456 patent, and ’250 patent†—none of which are currently involved | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
